Voluntis Shareholders’ Approval of the Securities Listing Transfer Project to the Euronext Growth Market in Paris
17 Dicembre 2020 - 7:06PM
Business Wire
Regulatory News:
At today's Ordinary General Meeting, the shareholders of
Voluntis (Euronext Paris, Ticker: VTX - ISIN: FR0004183960 - the
"Company"), a leader in the field of digital therapeutics,
who were present or represented approved unanimously the listing
transfer project of the Company's shares to Euronext Growth in
Paris (« Euronext Growth ») and empowered the Board of
Directors to carry out this transfer.
The Board of Directors, which met today following the Company's
ordinary general meeting, decided to implement this transfer.
Subject to the approval of Euronext, the listing of the Company's
securities on Euronext Growth will be carried out under an
accelerated procedure for the admission to the existing trading
shares, without the issuance of new shares.
Subject to Euronext's approval, Voluntis shares’ will be listed
on Euronext Growth within a minimum period of two months.
As a reminder, the Company announced on October 28, 2020 its
intention to transfer the listing of its shares to Euronext Growth,
a market more appropriate to its size.
DETAILS ON THE VOLUNTIS SECURITIES
LISTING TRANSFER:
- Consequences of the transfer
:
In accordance with current regulations, the Company wishes to
inform its shareholders of the possible consequences of such a
transfer:
- In terms of periodic financial
information: - The annual financial statements (parent
company and consolidated financial statements), the management
report and the statutory auditors' reports on these financial
statements would be published no later than four months after the
close. - The half-yearly financial statements and an activity
report would be published at the latest within four months of the
closing (instead of three months currently) with a limited review
by the statutory auditors. These methods of publication of the
half-yearly financial statements would take effect as of the
half-yearly financial statements on June 30, 2021. - The Company
has chosen, with an aim of transparency for its investors and
shareholders, to maintain the application of IFRS.
- In terms of protecting minority
shareholders: - Unless an exception is made, the protection
of the Company's minority shareholders is ensured on Euronext
Growth by the mechanism of a mandatory public offering in the event
that the threshold of 50% of the capital or voting rights is
crossed, directly or indirectly, alone or in concert. - The listed
companies on Euronext Growth are only required to disclose to the
market in terms of changes in share ownership to the market the
crossing of thresholds (upwards or downwards), thresholds of 50%
and 95% of the capital or voting rights. - However, both the public
offer law and the threshold crossing declaration obligations and
declarations of intent applicable to companies admitted to trading
on a regulated market will be maintained for a period of three
years from the date of admission of the Company's shares to trading
on Euronext Growth.
- In terms of permanent information:
- As Euronext Growth is an organized multilateral trading facility,
the Company will remain subject to the applicable provisions
regarding ongoing market disclosure and more specifically to the
provisions of EU Regulation 596/2014 of April 16, 2014 on Market
Abuse. - In addition, the management (and persons related to them)
of the Company will remain subject to the obligation to declare the
transactions they carry out on the shares and debt securities of
the Company.
Lastly, the Company draws attention to the fact that the
transfer to the Euronext Growth market could result in a change in
the liquidity of the share that differs from the liquidity observed
since the beginning of its listing on the regulated market of
Euronext in Paris.
- Provisional schedule of the operation1 :
December 17, 2020
- Approval by the shareholders of
Voluntis, following the Ordinary General Meeting, on the transfer
to the Euronext Growth market.
- Meeting of the Board of Directors
deciding to implement the authorization granted by the Ordinary
Shareholders' Meeting.
- Application to Euronext Paris S.A to
delist the Company's securities from the regulated market of
Euronext Paris and concomitant application for direct admission of
the securities on Euronext Growth.
- Publication of the press release
relating to the final decision on the request for transfer to
Euronext Growth.
No earlier than February 17,
2021 (depending on Euronext's instruction period).
- Delisting of Voluntis securities from
the regulated market of Euronext in Paris and admission of the
shares to the Euronext Growth market.
The Company will be supported in its transfer to Euronext Growth
by Gilbert Dupont as Listing sponsor.
About Voluntis
Voluntis creates digital therapeutics that empower people with
chronic conditions to self-manage their treatment every day, thus
improving real-world outcomes. Voluntis’ solutions, combining
mobile and web apps, use clinical algorithms to deliver
personalized recommendations to patients and their care teams. For
example, these recommendations are used to adjust treatment dosage,
manage side effects or monitor symptoms. Leveraging its Theraxium®
technology platform, Voluntis has designed and operates multiple
digital therapeutics, especially in oncology and diabetes. Voluntis
has long-standing partnerships with leading life science companies.
Based in Cambridge, MA, and Paris, France, Voluntis is a founding
member of the Digital Therapeutics Alliance. For more information,
please visit: www.voluntis.com
Mnemo : VTX - ISIN : FR0004183960
1 Subject to the approval of Euronext
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201217005946/en/
ACTUS Media relations Vivien Ferran
vferran@actus.fr +33 (0)1 53 67 36 34
ACTUS Investor relations Jérôme
Fabreguettes-Leib voluntis@actus.fr +33 (0)1 53 67 36 78
Voluntis Chief Financial Officer Guillaume
Floch investisseurs@voluntis.com +33 (0)1 41 38 39 20